Abstract 1485P
Background
Patients (pts) diagnosed with metastatic cancer often experience a high symptom burden and diminished health-related quality of life (HRQOL), which can significantly impact their overall well-being. Physical activity (PA) has emerged as a promising intervention to alleviate symptoms and improve HRQOL in this population. This study examines the effects of a 12-week supervised remote PA program on symptom burden and health-related quality of life (HRQOL) in pts diagnosed with metastatic cancer.
Methods
This prospective study included eligible pts undergoing treatment for metastatic cancer. Initial assessments and weekly exercise guidance were provided to pts via WhatsApp. Proper home exercise techniques were demonstrated using the Vedius platform. The prescribed exercise regimen entailed 3 to 5 hours per week (4 to 6 days a week) of combined resistance and aerobic exercises. Outcome measures, including symptom burden (Edmonton Symptom Assessment System, ESAS, scale 0-90) and overall quality of life (Functional Assessment of Cancer Therapy-General, FACT-G, scale 0-108) were evaluated at baseline and after 12 weeks. Data analysis involved descriptive statistics and the linear mixed models.
Results
A total of 62 pts, with a median age of 68 years (range: 32-88), were enrolled in the study. Among the participants, 54.8% were female, 66.1% were white, and 61.3% were married, with 57.7% holding a college degree. The most prevalent cancer types included breast (24.2%), genitourinary (19.4%), lung (14.5%), and gynecological (14.5%). Over the study period, a significant improvement was observed in symptom burden (baseline mean=21.7, follow-up mean=7.8, P=0.001) and HRQOL (baseline mean=83.4, follow-up mean=95.4, P=0.001).
Conclusions
Our findings demonstrates that a 12-week supervised remote PA program has a significant positive impact on symptom burden and HRQOL in pts with metastatic cancer undergoing treatment. These findings underscore the potential benefits of incorporating PA interventions into the management of metastatic cancer, offering a promising avenue for improving patient outcomes and well-being.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10